Guggenheim Maintains Buy on Spruce Biosciences, Lowers Price Target to $104

Benzinga Newsdesk www.benzinga.com Negative 61.9%

Neg 61.9% Neu 0% Pos 0%

Guggenheim analyst Debjit Chattopadhyay maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $123 to $104.